Humphrey fonge

Prof. Humphrey fonge

Department of Medical Imaging, College of Medicine, University of Saskatchewan, 103 Hospital Dr, Room 1566, Saskatoon, SK S7N 0W8, Canada
orcid

Research Focus & Metrics

Academic Career Length

20Years (2007-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
30 March 2018 in Oncotarget
Verified
Journal Article
Open access
RCRufael Chekol
Rufael Chekol
Viswas Raja SolomonViswas Raja Solomon
Viswas Raja Solomon
EAElahe Alizadeh
Elahe Alizadeh
WBWendy Bernhard
Wendy Bernhard
DFDarrell Fisher
Darrell Fisher
HFHumphrey fonge
Humphrey fonge
89 Zr-nimotuzumab for immunoPET imaging of epidermal growth factor receptor I 89Zr-nimotuzumab for immunopet imaging of epidermal growth factor receptor I

12 June 2018 in Molecular Imaging and Biology
Verified
Journal Article
Open access
PDF file
KAKausar Alam
Kausar Alam
AEAyman El-Sayed
Ayman El-Sayed
KBKris Barreto
Kris Barreto
WBWendy Bernhard
Wendy Bernhard
HFHumphrey fonge
Humphrey fonge
CGC Ronald Geyer
C Ronald Geyer
Construction of antibody-based, molecular-targeted optical imaging probes requires the labeling of an antibody with a fluorophore. The most common method for doing this involves non-specifically conjugating a fluorophore to an antibody, resulting in poorly defined, heterogeneous imaging probes that often have suboptimal in vivo behavior. We tested a new strategy to site-specific label antibody-based imaging probes using the SpyCatcher/SpyTag protein ligase system.

13 September 2019 in Molecular Pharmaceutics
Verified
Journal Article
Closed access
Viswas Raja SolomonViswas Raja Solomon
Viswas Raja Solomon
EAElahe Alizadeh
Elahe Alizadeh
WBWendy Bernhard
Wendy Bernhard
SHSiddesh V. Hartimath
Siddesh V. Hartimath
WHWayne Hill
Wayne Hill
HFHumphrey fonge
Humphrey fonge

1 January 2018 in Theranostics
Verified
Journal Article
Open access
AEAyman El-Sayed
Ayman El-Sayed
WBWendy Bernhard
Wendy Bernhard
KBKris Barreto
Kris Barreto
CGCarolina Gonzalez
Carolina Gonzalez
WHWayne Hill
Wayne Hill
CGC Ronald Geyer
C Ronald Geyer
In vivo imaging is influenced by the half-life, tissue penetration, biodistribution, and affinity of the imaging probe. Immunoglobulin G (IgG) is composed of discrete domains with known functions, providing a template for engineering antibody fragments with desired imaging properties. Here, we engineered antibody-based imaging probes, consisting of different combinations of antibody domains, labeled them with the near-infrared fluorescent dye IRDye800CW, and evaluated their in vivo imaging properties. Antibody-based imaging probes were based on an anti-HER3 antigen binding fragment (Fab) isolated using phage display.

17 January 2019 in Journal of Nuclear Medicine
Verified
Journal Article
Open access
PDF file
Siddesh V HartimathSiddesh V Hartimath
Siddesh V Hartimath
EAElahe Alizadeh
Elahe Alizadeh
Viswas Raja SolomonViswas Raja Solomon
Viswas Raja Solomon
RCRufael Chekol
Rufael Chekol
WBWendy Bernhard
Wendy Bernhard
HFHumphrey fonge
Humphrey fonge
Background: Epidermal growth factor receptor I (EGFR) is overexpressed in most cancers of epithelial origin. Antibody drug conjugates (ADCs) with PEGylated-maytansine (PEG-DM1) show promise in vitro and in vivo. However, in vivo biodistribution data for ADCs with PEG-DM1 have not been reported. Development of methods to understand the real-time in vivo behaviour of these ADCs is needed to move these compounds to the clinic. Methods: Here we have used non-invasive µSPECT/CT imaging and ex vivo biodistribution to understand the in vivo behaviour of PEG6-DM1 ADCs. We developed nimotuzumab ADCs conjugated to PEG6-DM1. We generated immunoconjugates with low (nimotuzumab-PEG6-DM1-Low) and high (nimotuzumab-PEG6-DM1-High) drug to antibody ratios (DAR). The DAR of nimotuzumab-PEG6-DM1-Low and nimotuzumab-PEG6-DM1-High was 3.5 and 7.3, respectively. Quality control was performed using UV spectrophotometry, size exclusion HPLC, bioanalyzer, biolayer interferometry, and flow cytometry in EGFR-positive DLD-1 cells. These immunoconjugates were conjugated with DOTA and radiolabeled with 111In. The in vitro binding and internalization rates of 111In-nimotuzumab, 111In-nimotuzumab-PEG6-DM1-Low and 111In-nimotuzumab-PEG6-DM1-High were characterized. Furthermore, the pharmacokinetics, biodistribution and imaging characteristics were evaluated in normal and DLD-1 tumor bearing mice. Results: Flow cytometry and biolayer interferometry showed a trend towards decreasing EGFR affinity with increasing number of PEG6-DM1 on the antibody. Despite the lower overall cellular binding of the PEG6-DM1 radioimmunoconjugates, internalization was higher for PEG6-DM1 ADCs than for the non-PEGylated ADC in the following order: 111In-nimotuzumab-PEG6-DM1-High > 111In-nimotuzumab-PEG6-DM1-Low > 111In-nimotuzumab. Nuclear uptake of 111In-nimotuzumab-PEG6-DM1-High was 4.4-fold higher than 111In-nimotuzumab. Pharmacokinetics and biodistribution showed 111In-nimotuzumab-PEG6-DM1-High had the slowest blood and whole body clearance rate. Uptake in DLD-1 tumors of 111In-nimotuzumab was similar to 111In-nimotuzumab-PEG6-DM1-Low but was significantly higher than for 111In-nimotuzumab-PEG6-DM1-High. Tumor-to-background ratios for 111In-nimotuzumab and 111In-nimotuzumab-PEG6-DM1-Low were higher than for 111In-nimotuzumab-PEG6-DM1-High. Conclusion: The results show that conjugation of multiple PEG6-DM1 reduces the affinity for EGFR in vitro. However, the reduced affinity is counteracted by the high internalization rate of constructs with PEG6-DM1 ADCs in vitro. The decreased affinity resulted in low tumor uptake of 111In-nimotuzumab-PEG6-DM1-High with a slow overall whole body clearance rate. This data provides insights for evaluating the pharmacokinetics, normal tissue toxicity and in determining dosing rate of PEGylated ADCs.

20 November 2020 in Cancers
Verified
Journal Article
Open access
PDF file
Viswas Raja SolomonViswas Raja Solomon
Viswas Raja Solomon
KBKris Barreto
Kris Barreto
WBWendy Bernhard
Wendy Bernhard
EAElahe Alizadeh
Elahe Alizadeh
PCPatrick Causey
Patrick Causey
HFHumphrey fonge
Humphrey fonge
To develop imaging and therapeutic agents, antibodies are often conjugated randomly to a chelator/radioisotope or drug using a primary amine (NH2) of lysine or sulfhydryl (SH) of cysteine. Random conjugation to NH2 or SH groups can require extreme conditions and may affect target recognition/binding and must therefore be tested. In the present study, nimotuzumab was site-specifically labeled using ∆N-SpyCatcher/SpyTag with different chelators and radiometals. Nimotuzumab is a well-tolerated anti-EGFR antibody with low skin toxicities. First, ΔN-SpyCatcher was reduced using tris(2-carboxyethyl)phosphine (TCEP), which was followed by desferoxamine-maleimide (DFO-mal) conjugation to yield a reactive ΔN-SpyCatcher-DFO. The ΔN-SpyCatcher-DFO was reacted with nimotuzumab-SpyTag to obtain stable nimotuzumab-SpyTag-∆N-SpyCatcher-DFO. Radiolabeling was performed with 89Zr, and the conjugate was used for the in vivo microPET imaging of EGFR-positive MDA-MB-468 xenografts. Similarly, ∆N-SpyCatcher was conjugated to an eighteen-membered macrocyclic chelator macropa-maleimide and used to radiolabel nimotuzumab-SpyTag with actinium-225 (225Ac) for in vivo radiotherapy studies. All constructs were characterized using biolayer interferometry, flow cytometry, radioligand binding assays, HPLC, and bioanalyzer. MicroPET/CT imaging showed a good tumor uptake of 89Zr-nimotuzumab-SpyTag-∆N-SpyCatcher with 6.0 ± 0.6%IA/cc (n = 3) at 48 h post injection. The EC50 of 225Ac-nimotuzumab-SpyTag-∆N-SpyCatcher and 225Ac-control-IgG-SpyTag-∆N-SpyCatcher against an EGFR-positive cell-line (MDA-MB-468) was 3.7 ± 3.3 Bq/mL (0.04 ± 0.03 nM) and 18.5 ± 4.4 Bq/mL (0.2 ± 0.04 nM), respectively. In mice bearing MDA-MB-468 EGFR-positive xenografts, 225Ac-nimotuzumab-SpyTag-∆N-SpyCatcher significantly (p = 0.0017) prolonged the survival of mice (64 days) compared to 225Ac-control IgG (28.5 days), nimotuzumab (28.5 days), or PBS-treated mice (30 days). The results showed that the conjugation and labeling using SpyTag/∆N-SpyCatcher to nimotuzumab did not significantly (p > 0.05) alter the receptor binding of nimotuzumab compared with a non-specific conjugation approach. 225Ac-nimotuzumab-SpyTag-∆N-SpyCatcher was effective in vitro and in an EGFR-positive triple negative breast cancer xenograft model.